You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.


Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of NTM Lung Disease

  • Authors: Patrick A. Flume, MD
  • CME Released: 6/26/2019
  • Valid for credit through: 6/26/2020
Start Activity

Target Audience and Goal Statement

This activity is intended for infectious diseases/HIV specialists, pulmonologists, and primary care physicians.

The goal of this activity is to increase clinician awareness of data regarding existing and emerging therapies for nontuberculous mycobacterial (NTM) lung disease.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Issues of sustaining efficacy of multidrug regimens for NTM lung disease over the long term
    • Common adverse events associated with traditional and novel multidrug regimens for treatment-refractory NTM lung disease
  • Have greater competence related to
    • Selecting appropriate therapy for individual patients with NTM lung disease, particularly those with treatment-refractory disease


As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


  • Patrick A Flume, MD

    Professor of Medicine and Pediatrics
    Medical University of South Carolina
    Charleston, South Carolina


    Disclosure: Patrick A. Flume, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: Corbus Pharmaceuticals Holdings, Inc.; Eloxx Pharmaceuticals; Horizon Pharma; Insmed Incorporated; Ionis Pharmaceuticals; McKesson Corporation; Novartis Pharmaceuticals Corporation; Proteostasis Therapeutics, Inc.; Savara Inc.; Vertex Pharmaceuticals Incorporated
    Received grants for clinical research from: Corbus Pharmaceuticals Holdings, Inc.; Galapagos NV; Insmed Incorporated; Novartis Pharmaceuticals Corporation; Novoteris; Proteostasis Therapeutics, Inc.; Savara Inc.; Sound Pharmaceuticals; Vertex Pharmaceuticals Incorporated


  • Emilie McCardell

    Freelance Medical Education Director


    Disclosure: Emilie McCardell has disclosed no relevant financial relationships.

CME Reviewer(s)

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC


    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Medscape, LLC staff have disclosed that they have no relevant financial relationships.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.


Balancing the Risks and Benefits of Multidrug Regimens in the Clinical Management of NTM Lung Disease

Authors: Patrick A. Flume, MDFaculty and Disclosures

CME Released: 6/26/2019

Valid for credit through: 6/26/2020


  • Print